How to Get Tirzepatide: Brand vs. Compounded & All Access Routes
Compare prescription routes for Mounjaro, Zepbound and patient-specific compounded tirzepatide, with product differences, payment checks and pharmacy safeguards.
Choose the product for the medical need
Start with the actual indication and prescription. Mounjaro prescribing information covers glycemic control in adults and children aged 10 or older with type 2 diabetes, plus reduction of major cardiovascular events in adults with type 2 diabetes at high risk. Mounjaro is not approved for weight management. Zepbound prescribing information covers long-term weight reduction in eligible adults and moderate to severe obstructive sleep apnea in adults with obesity. The active ingredient is shared; approved uses, product instructions and payment programs differ.
Get a prescription and verify the care pathway
A licensed clinician must assess whether treatment is appropriate; an online questionnaire does not guarantee a prescription. Discuss the diagnosis, current medicines, previous reactions, pregnancy plans and relevant conditions. Ask who handles side effects and follow-up. Coverage requires checking the actual plan’s formulary, indication, prior authorization and pharmacy network; prescribing online or in person does not guarantee approval. Appointment, authorization, dispensing and shipping times vary.
Use FDA BeSafeRx to check the pharmacy’s state license and warning signs. Confirm the prescriber can practice where you are, the actual dispensing pharmacy, the product supplied and how to reach a pharmacist. A seller offering prescription medicine without an appropriate evaluation and prescription, obscuring its pharmacy, or calling a compound an FDA-approved generic raises a specific concern. A low advertised price by itself does not prove a product is counterfeit.
Compare the full cost of access
Compare the exact product, strength, 28-day quantity and total paid amount. A clinic membership may exclude medication, laboratory work, visits, shipping or supplies. Introductory pricing may differ from ongoing fills. Do not assume a flat fee at every strength, fixed percentage savings versus retail, or that a higher price buys a verified quality tier. Request a written itemized quote and cancellation/refund terms before paying.
For obesity treatment, check Zepbound’s current self-pay options rather than assuming the list price is the cash price. Mounjaro savings eligibility is a different program and includes commercial-insurance requirements. LillyDirect is a dispensing/access service, not a promise of free tirzepatide.
When patient-specific compounding enters the decision
Compounding is a patient-specific medical decision, not an FDA-approved generic alternative. FDA’s current compounding policy distinguishes section 503A prescriptions and restrictions on making essentially copies from the separate section 503B bulk-substance and copy requirements. A prescriber-documented significant difference for an identified patient matters under 503A; cost or a prescription alone does not remove federal restrictions. Shortage-related enforcement discretion for tirzepatide ended in 2025. The April 2026 503B proposal is a proposal, not a final blanket prohibition on all compounding.
FDA-approved and compounded medicines have different evidence and oversight. FDA’s GLP-1 safety guidance explains that compounded products are not reviewed before marketing for safety, effectiveness or quality. Pharmacy licensing, accreditation, price and customer reviews do not establish equivalence to the approved product or guarantee a particular vial’s potency or sterility. Research-use vials are not prescription medication for home treatment.
Use the exact prescription and presentation
Mounjaro starts at 2.5 mg once weekly; further 2.5 mg increases require additional glycemic need and at least four weeks at the current dose. Its maximum is 15 mg weekly in adults and 10 mg in pediatric patients. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at a dose and consideration of response and tolerability. Weight-management maintenance options are 5, 10 or 15 mg; OSA maintenance is 10 or 15 mg. The maximum is not a goal for everyone. Use the Mounjaro label or Zepbound label for the prescribed presentation.
For compounded GLP-1 vials containing multiple doses, FDA advises discarding the vial within 28 days after first use even if the compounder says it can be used longer; an earlier beyond-use date still applies. Use a fresh sterile needle and syringe each time. This is distinct from the presentation-specific instructions for approved Mounjaro or Zepbound. Ask the dispensing pharmacist to reconcile the prescribed milligrams, concentration, measured volume, storage and discard dates before use. Do not use a general peptide calculator or research-vial mixing guide as the prescription.
The labels contraindicate treatment with a personal or family history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to the product. Other history, including pancreatitis and severe gastrointestinal disease, needs clinical assessment rather than an automatic online eligibility rule. Severe persistent abdominal pain, repeated vomiting with dehydration, or an allergic reaction needs prompt care. Tell the prescriber about oral contraception and planned procedures; do not combine tirzepatide products or add another GLP-1 drug on your own.
Plan follow-up before the first fill
Agree on how symptoms, glucose where relevant, weight response, nutrition and affordability will be reviewed. Ask the pharmacist about the exact strength and refill date, and contact the prescriber if stock or cost interrupts treatment. Do not change strength, combine products or reconstitute a research vial to bridge a delay. Related access and reconstitution links below provide context; they do not replace product-specific pharmacy instructions.
Frequently Asked Questions
Tirzepatide is the active ingredient in both brands. Mounjaro treats type 2 diabetes and has a specified cardiovascular risk-reduction indication in adults with type 2 diabetes; Zepbound has adult weight-management and obesity-related OSA indications. Product instructions and payment programs differ.
A pharmacy-prepared formulation for an individual clinical need. It is not an FDA-approved generic of Mounjaro or Zepbound, and equivalence in safety, effectiveness or quality has not been established.
A prescription and a pharmacy license alone do not settle this. Section 503A and 503B have distinct federal requirements, including restrictions on essentially copies and bulk ingredients; patient-specific need and prescriber documentation matter. See FDA sources in the article.
There is no universal saving. Compare a written quote for the prescribed quantity and all care fees against the exact brand, maintenance strength and available self-pay or insurance program.
Prescription treatment requires evaluation and a valid prescription from an appropriately licensed clinician. Research-use vials sold without that pathway are not prescription medicine for home treatment.
The shortage-based enforcement-discretion periods ended in 2025. That is not the same as a temporary FDA approval of compounded drugs or a blanket ban on every patient-specific compound. Current 503A/503B requirements still apply.
Timing depends on the evaluation, lawful prescription, pharmacy preparation, stock and delivery. A universal 3–7-day turnaround or faster-than-brand promise is not established.
Assess an FDA-approved product first with the clinician. If it cannot meet the medical need, discuss whether patient-specific compounding is appropriate and legally available; cost alone does not establish equivalence or an exemption.